Hangcheng Fu

928 total citations
33 papers, 713 citations indexed

About

Hangcheng Fu is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Hangcheng Fu has authored 33 papers receiving a total of 713 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Surgery, 12 papers in Pulmonary and Respiratory Medicine and 11 papers in Oncology. Recurrent topics in Hangcheng Fu's work include Bladder and Urothelial Cancer Treatments (13 papers), Renal cell carcinoma treatment (11 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Hangcheng Fu is often cited by papers focused on Bladder and Urothelial Cancer Treatments (13 papers), Renal cell carcinoma treatment (11 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Hangcheng Fu collaborates with scholars based in China, United States and Israel. Hangcheng Fu's co-authors include Jiejie Xu, Yu Zhu, Huyang Xie, Qiang Fu, Junyu Zhang, Bo Dai, Le Xu, Zewei Wang, Zheng Liu and Weijuan Zhang and has published in prestigious journals such as Clinical Cancer Research, British Journal of Cancer and European Urology.

In The Last Decade

Hangcheng Fu

32 papers receiving 702 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hangcheng Fu China 14 296 278 270 234 175 33 713
Tomoyuki Uchihara Japan 13 307 1.0× 126 0.5× 263 1.0× 187 0.8× 153 0.9× 30 654
David Borg Sweden 12 391 1.3× 141 0.5× 194 0.7× 177 0.8× 164 0.9× 20 617
Takumi Yamaura Japan 13 329 1.1× 156 0.6× 200 0.7× 215 0.9× 63 0.4× 38 603
Chunhui Zhang China 13 324 1.1× 184 0.7× 210 0.8× 102 0.4× 112 0.6× 31 650
Hélène Hovington Canada 14 145 0.5× 171 0.6× 232 0.9× 201 0.9× 180 1.0× 34 604
Ruochuan Zang China 17 413 1.4× 142 0.5× 410 1.5× 329 1.4× 69 0.4× 38 870
Prateek Mendiratta United States 13 240 0.8× 123 0.4× 184 0.7× 256 1.1× 83 0.5× 37 584
Go Masuda Japan 15 215 0.7× 137 0.5× 354 1.3× 114 0.5× 74 0.4× 35 632
Shigemasa Suzuki Japan 16 155 0.5× 93 0.3× 335 1.2× 187 0.8× 226 1.3× 48 745

Countries citing papers authored by Hangcheng Fu

Since Specialization
Citations

This map shows the geographic impact of Hangcheng Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hangcheng Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hangcheng Fu more than expected).

Fields of papers citing papers by Hangcheng Fu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hangcheng Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hangcheng Fu. The network helps show where Hangcheng Fu may publish in the future.

Co-authorship network of co-authors of Hangcheng Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Hangcheng Fu. A scholar is included among the top collaborators of Hangcheng Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hangcheng Fu. Hangcheng Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Fu, Hangcheng, et al.. (2024). INGESTION OF INORGANIC ARSENIC IN DRINKING WATER INDUCED UROGENITAL CARCINOGENESIS IN MICE MODELS. Urologic Oncology Seminars and Original Investigations. 42. S35–S35. 1 indexed citations
3.
Fu, Hangcheng, et al.. (2024). Comparison of the perioperative outcomes of using the Firefly system with indocyanine green during robotic‐assisted cystectomy with urinary diversion. International Journal of Urology. 31(6). 646–652. 1 indexed citations
4.
Fu, Hangcheng, et al.. (2024). Identify risk factors for perioperative outcomes in Intracorporeal Urinary Diversion and Extracorporeal Urinary Diversion with Robotic Cystectomy. International braz j urol. 50(2). 178–191. 1 indexed citations
5.
Tyagi, Bhawna, Balaji Chandrasekaran, Ashish Tyagi, et al.. (2023). Exposure of environmental trace elements in prostate cancer patients: A multiple metal analysis. Toxicology and Applied Pharmacology. 479. 116728–116728. 10 indexed citations
6.
7.
8.
9.
Liang, Lifan, Jing Li, Hangcheng Fu, Xinyang Liu, & Peng Liu. (2019). Identification of High Serum Apolipoprotein A1 as a Favorable Prognostic Indicator in Patients with Multiple Myeloma. Journal of Cancer. 10(20). 4852–4859. 17 indexed citations
10.
Fu, Hangcheng, Yu Zhu, Yiwei Wang, et al.. (2018). Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer. Clinical Cancer Research. 24(13). 3069–3078. 127 indexed citations
11.
Xie, Huyang, Yu Zhu, Junyu Zhang, et al.. (2018). B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients. BMC Cancer. 18(1). 590–590. 14 indexed citations
12.
Fu, Qiang, Le Xu, Yiwei Wang, et al.. (2018). Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion. European Urology. 75(5). 752–763. 164 indexed citations
13.
Liu, Zheng, Yu Zhu, Le Xu, et al.. (2018). Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer. OncoImmunology. 7(9). e1474317–e1474317. 64 indexed citations
14.
Zhang, Junyu, Yu Zhu, Yiwei Wang, et al.. (2017). Prognostic and Predictive Value of O6-methylguanine Methyltransferase for Chemotherapy in Patients with Muscle-Invasive Bladder Cancer. Annals of Surgical Oncology. 25(1). 342–348. 4 indexed citations
15.
Liu, Yidong, Qiang Fu, Zewei Wang, et al.. (2017). Galectin-9 as a prognostic and predictive biomarker in bladder urothelial carcinoma. Urologic Oncology Seminars and Original Investigations. 35(6). 349–355. 22 indexed citations
16.
Dong, Fan, Hangcheng Fu, Xiao Shi, et al.. (2017). How do organ-specific metastases affect prognosis and surgical treatment for patients with metastatic upper tract urothelial carcinoma: first evidence from population based data. Clinical & Experimental Metastasis. 34(8). 467–477. 17 indexed citations
17.
Wang, Zewei, Huyang Xie, Lin Zhou, et al.. (2016). CCL2/CCR2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma. Oncotarget. 7(32). 51525–51534. 37 indexed citations
18.
Fu, Hangcheng, Yu Zhu, Yiwei Wang, et al.. (2016). Tumor Infiltrating Mast Cells (TIMs) Confers a Marked Survival Advantage in Nonmetastatic Clear-Cell Renal Cell Carcinoma. Annals of Surgical Oncology. 24(5). 1435–1442. 35 indexed citations
19.
Fu, Hangcheng, Yidong Liu, Le Xu, et al.. (2015). Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma. Tumor Biology. 36(8). 5791–5799. 32 indexed citations
20.
Fu, Qiang, Yuan Chang, Huimin An, et al.. (2015). Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis. British Journal of Cancer. 113(11). 1581–1589. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomoyuki Uchihara Breakdown of academic impact, for papers by David Borg Breakdown of academic impact, for papers by Takumi Yamaura Breakdown of academic impact, for papers by Chunhui Zhang Breakdown of academic impact, for papers by Hélène Hovington Breakdown of academic impact, for papers by Ruochuan Zang Breakdown of academic impact, for papers by Prateek Mendiratta Breakdown of academic impact, for papers by Go Masuda Breakdown of academic impact, for papers by Shigemasa Suzuki
Rankless by CCL
2026